Monoclonal antibodies targeting ANGPT2 have demonstrated efficacy in preclinical studies by blocking its action, leading to the inhibition of tumor angiogenesis and a reduction in tumor growth and metastasis. Here, ANGPT2 is linked to neoplasm.